1. De Oliveira DM, Forde BM, Kidd TJ, Harris PN, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev 2020;33:e00181-19. [DOI:10.1128/CMR.00181-19]

2. Rosa TF, Coelho SS, Foletto VS, Bottega A, Serafin MB, Machado CdS, et al. Alternatives for the treatment of infections caused by ESKAPE pathogens. J Clin Pharmacy Ther 2020;45: 863-73. [DOI:10.1111/jcpt.13149]

3. Kyriakidis I, Vasileiou E, Pana ZD, Tragiannidis A. Acinetobacter baumannii antibiotic resistance mechanisms. Pathogens 2021;10:373. [DOI:10.3390/pathogens10030373]

4. Whiteway C, Breine A, Philippe C, Van der Henst C. Acinetobacter baumannii. Trends Microbiol 2022;30:199-200. [DOI:10.1016/j.tim.2021.11.008]

5. Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics 2020;9:119. [DOI:10.3390/antibiotics9030119]

6. Zaidan N, Hornak JP, Reynoso D. Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother 2021;65: e0092421. [DOI:10.1128/AAC.00924-21]

7. Jeon JH, Jang K-M, Lee JH, Kang L-W, Lee SH. Transmission of antibiotic resistance genes through mobile genetic elements in Acinetobacter baumannii and gene-transfer prevention. Sci Total Environ 2023;857:159497. [DOI:10.1016/j.scitotenv.2022.159497]

8. Nguyen M, Joshi S. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review. J Appl Microbiol 2021;131:2715-38. [DOI:10.1111/jam.15130]

9. Takebayashi Y, Findlay J, Heesom KJ, Warburton PJ, Avison MB, Evans BA. Variability in carbapenemase activity of intrinsic OxaAb (OXA-51-like) β-lactamase enzymes in Acinetobacter baumannii. J Antimicrob Chemother 2021;76:587-95. [DOI:10.1093/jac/dkaa502]

10. Falcone M, Tiseo G, Leonildi A, Della Sala L, Vecchione A, Barnini S, et al. Cefiderocol-compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2022;66:e02142-21. [DOI:10.1128/aac.02142-21]

11. Levi I, Rubinstein E. Acinetobacter infections-overview of clinical features. Acinetobacter 2020:101-15. [DOI:10.1201/9781003069263-5]

12. Rai S, Dash D, Agarwal N. Introducing the new face of CLSI M100 in 2023: An explanatory review. Indian J Med Microbiol 2023;46:100432. [DOI:10.1016/j.ijmmb.2023.100432]

13. Kolesnik-Goldmann N, Seth-Smith HM, Haldimann K, Imkamp F, Roloff T, Zbinden R, et al. Comparison of Disk Diffusion, E-Test, and Broth Microdilution Methods for Testing In Vitro Activity of Cefiderocol in Acinetobacter baumannii. Antibiotics 2023;12:1212. [DOI:10.3390/antibiotics12071212]

14. Kumari M, Bhattarai NR, Rai K, Pandit TK, Khanal B. Multidrug‐Resistant Acinetobacter: Detection of ESBL, MBL, blaNDM-1 Genotype, and Biofilm Formation at a Tertiary Care Hospital in Eastern Nepal. Int J Microbiol 2022;2022:8168000. [DOI:10.1155/2022/8168000]

15. Patidar N, Vyas N, Sharma S, Sharma B. Phenotypic detection of carbapenemase production in carbapenem-resistant enterobacteriaceae by modified hodge test and modified strip Carba NP test. J Lab Physicians 2021;13:14-21. [DOI:10.1055/s-0041-1723859]

16. El-Kazzaz W, Metwally L, Yahia R, Al-Harbi N, El-Taher A, Hetta HF. Antibiogram, prevalence of OXA carbapenemase encoding genes, and RAPD-genotyping of multidrug-resistant Acinetobacter baumannii incriminated in hidden community-acquired infections. Antibiotics 2020;9:603. [DOI:10.3390/antibiotics9090603]

17. Najafikhah A, Hakemi-Vala M, Samavat S, Nasiri MJ. Molecular Analysis of Fosfomycin Resistance Among Escherichia coli Isolates From Urinary Tract Infections in Kidney Transplant Patients During 2019-2020. Arch Clin Infect Dis 2023;18:e132120. [DOI:10.5812/archcid-132120]

18. Ilbeigi K, Askari Badouei M, Vaezi H, Zaheri H, Aghasharif S, Kafshdouzan K. Molecular survey of mcr1 and mcr2 plasmid mediated colistin resistance genes in Escherichia coli isolates of animal origin in Iran. BMC Res Notes 2021;14:1-5. [DOI:10.1186/s13104-021-05519-6]

19. Willems RP, van Dijk K, Vehreschild MJ, Biehl LM, Ket JC, Remmelzwaal S, Vandenbroucke-Grauls CM. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis 2023;23:719-31. [DOI:10.1016/S1473-3099(22)00811-8]

20. Hansen GT. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among Enterobacterales and other Gram-negative bacteria. Infect Dis Ther 2021;10:75-92. [DOI:10.1007/s40121-020-00395-2]

21. Gedefie A, Demsis W, Ashagrie M, Kassa Y, Tesfaye M, Tilahun M, et al. Acinetobacter baumannii biofilm formation and its role in disease pathogenesis: a review. Infect Drug Resist 2021:3711-9. [DOI:10.2147/IDR.S332051]

22. Appaneal HJ, Lopes VV, LaPlante KL, Caffrey AR. Treatment, clinical outcomes, and predictors of mortality among a national cohort of admitted patients with Acinetobacter baumannii infection. Antimicrob Agents Chemother 2022;66(3):e01975-21. [DOI:10.1128/aac.01975-21]

23. Farajzadeh Sheikh A, Savari M, Abbasi Montazeri E, Khoshnood S. Genotyping and molecular characterization of clinical Acinetobacter baumannii isolates from a single hospital in Southwestern Iran. Pathog Glob Health 2020;114:251-61. [DOI:10.1080/20477724.2020.1765124]

24. Noshadi S, Khodavandi A. Expression analysis of drug-resistant gene (blaOXA-51) in carbapenemases producing Acinetobacter baumannii treated with imipenem/sulbactam combination. Braz J Pharm Sci 2021;57:e19048. [DOI:10.1590/s2175-97902020000419048]

25. Girija AS. Acinetobacter baumannii as an oro-dental pathogen: a red alert!! J Appl Oral Sci 2024;32:e20230382. [DOI:10.1590/1678-7757-2023-0382]

26. Abd El-Baky RM, Farhan SM, Ibrahim RA, Mahran KM, Hetta HF. Antimicrobial resistance pattern and molecular epidemiology of ESBL and MBL producing Acinetobacter baumannii isolated from hospitals in Minia, Egypt. Alexandria J Med 2020;56:4-13. [DOI:10.1080/20905068.2019.1707350]

27. Zarabadi-Pour M, Peymani A, Habibollah-Pourzereshki N, Sarookhani MR, Karami AA, Javadi A. Detection of Extended-Spectrum ß-Lactamases among Acinetobacter Baumannii Isolated from Hospitals of Qazvin, Iran. Ethiop J Health Sci 2021;31:229-36. [DOI:10.4314/ejhs.v31i2.4]

28. Moradi J, Hashemi FB, Bahador A. Antibiotic resistance of Acinetobacter baumannii in Iran: a systemic review of the published literature. Osong Public Health Res Perspect 2015;6:79-86. [DOI:10.1016/j.phrp.2014.12.006]

29. Yazdansetad S, Najari E, Ghaemi EA, Javid N, Hashemi A, Ardebili A. Carbapenem-resistant Acinetobacter baumannii isolates carrying blaOXA genes with upstream ISAba1: First report of a novel OXA subclass from Iran. J Glob Antimicrob Resist 2019;18:95-99. [DOI:10.1016/j.jgar.2018.12.011]

30. Emergence of Rifampicin, Tigecycline, and Colistin-Resistant Acinetobacter baumannii in Iran; Spreading of MDR Strains of Novel International Clone Variants. Microb Drug Resist 2013;19:397-406. [DOI:10.1089/mdr.2012.0233]

31. Aghapour Z, Hasani A, Aghazadeh M, Rezaee MA, Ganbarov K, Pourlak T, et al. Genes involved in colistin resistance of gram-negative isolates in the northwest of Iran. Gene Reports 2019;14:81-6. [DOI:10.1016/j.genrep.2018.12.001]

32. Moosavian M, Emam N. The first report of emerging mobilized colistin-resistance (mcr) genes and ERIC-PCR typing in Escherichia coli and Klebsiella pneumoniae clinical isolates in southwest Iran. Infect Drug Resist 2019;12:1001. [DOI:10.2147/IDR.S192597]

33. Kareem SM. Emergence of mcr-and fosA3-mediated colistin and fosfomycin resistance among carbapenem-resistant Acinetobacter baumannii in Iraq. Meta Gene 2020;25:100708. [DOI:10.1016/j.mgene.2020.100708]

34. Abdulateef SA, Al-Salmani MS, Owaif HAA. Acinetobacter baumannii producing ESBLs and carbapenemases in the Intensive Care Units developing fosfomycin and colistin resistance. Journal of Applied and Natural Science 2023;15:1263-67. [DOI:10.31018/jans.v15i3.4872]

35. Ghanavati R, Ohadi E, Kazemian H, Yazdani F, Torki A, Kalani BS, et al. Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran. Recent Pat Antiinfect Drug Discov 2018;13:180-86. [DOI:10.2174/1574891X13666180517075803]